Host genetic determinants of T cell responses to the MRKAd5 HIV-1 gag/pol/nef vaccine in the step trial

Journal of Infectious Diseases

Volumn 203, Issue 6, 2011, Pages 773-779

  Fellay, Jacques ^a   Frahm, Nicole ^b   Shianna, Kevin V ^a   Cirulli, Elizabeth T ^a   Casimiro, Danilo R ^c   Robertson, Michael N ^c   Haynes, Barton F ^a   Geraghty, Daniel E ^b   McElrath, M Juliana ^b   Goldstein, David B ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; GAMMA INTERFERON; HLA B ANTIGEN; HLA C ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEF PROTEIN; POL PROTEIN;

ADENOVIRUS 5; ADULT; ALLELE; AMERICAN INDIAN; ARTICLE; ASIAN; CAUCASIAN; CELLULAR IMMUNITY; CONTROLLED STUDY; DISEASE CONTROL; DRUG DESIGN; ENZYME LINKED IMMUNOSPOT ASSAY; ETHNIC DIFFERENCE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; IMMUNOGENETICS; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; NEGRO; PACIFIC ISLANDER; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

ADULT; AIDS VACCINES; CD8-POSITIVE T-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE PRODUCTS, GAG; GENES, GAG; GENES, NEF; GENES, POL; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; REGRESSION ANALYSIS; T-LYMPHOCYTES; YOUNG ADULT;

EID: 79952332498     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jiq125     Document Type: Article

References (27)

1. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372:1881-93.
2. McElrath MJ, De Rosa SC, Moodie Z, et al. HIV-1 vaccine-induced immunity in the test-of-concept Step study: a case-cohort analysis. Lancet 2008; 372:1894-905.
3. Catanzaro AT, Koup RA, Roederer M, et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis 2006; 194:1638-49. (Pubitemid 44901994)
4. Priddy FH, Brown D, Kublin J, et al. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis 2008; 46:1769-81. (Pubitemid 351706778)
5. McCarthy MI, Abecasis GR, Cardon LR, et al. Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat Rev Genet 2008; 9:356-69. (Pubitemid 351556063)
6. Moodie Z, Huang Y, Gu L, Hural J, Self SG. Statistical positivity criteria for the analysis of ELISpot assay data in HIV-1 vaccine trials. J Immunol Methods 2006; 315:121-32. (Pubitemid 44419512)
7. Moodie Z, Price L, Gouttefangeas C, et al. Response definition criteria for ELISPOT assays revisited. Cancer Immunol Immunother 2010; 59:1489-501.
8. Wang K, Li M, Hadley D, et al. PennCNV: an integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. Genome Res 2007; 17:1665-74. (Pubitemid 350074862)
9. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies 2006; 38:904-9.
10. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81:559-75. (Pubitemid 47330214)
11. Whitlock MC. Combining probability from independent tests: the weighted Z-method is superior to Fisher's approach. J Evol Biol 2005; 18:1368-73. (Pubitemid 41725687)
12. Goulder PJ, Watkins DI. Impact of MHC class I diversity on immune control of immunodeficiency virus replication. Nat Rev Immunol 2008; 8:619-30.
13. Migueles SA, Sabbaghian MS, Shupert WL, et al. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci U S A 2000; 97:2709-14. (Pubitemid 30159236)
14. Altfeld M, Addo MM, Rosenberg ES, et al. Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection. IDS 2003; 17:2581-91. (Pubitemid 38402336)
15. Fellay J, Shianna KV, Ge D, et al. A whole-genome association study of major determinants for host control of HIV-1. Science 2007; 317:944-7. (Pubitemid 47301321)
16. Fellay J, Ge D, Shianna KV, et al. Common genetic variation and the control of HIV-1 in humans. PLoS Genet 2009; 5:e1000791.
17. Pelak K, Goldstein DB, Walley NM, et al. Host determinants of HIV-1 control in African Americans. J Infect Dis 2010; 201:1141-9.
18. Goulder PJ, Phillips RE, Colbert RA, et al. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med 1997; 3:212-7. (Pubitemid 27064707)
19. Schneidewind A, Brockman MA, Yang R, et al. Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication. J virol 2007; 81:12382-93. (Pubitemid 350085852)
20. Kaslow RA, Carrington M, Apple R, et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med 1996; 2:405-11. (Pubitemid 26193012)
21. Kawashima Y, Pfafferott K, Frater J, et al. Adaptation of HIV-1 to human leukocyte antigen class I. Nature 2009; 458:641-5.
22. Steel CM, Ludlam CA, Beatson D, et al. HLA haplotype A1 B8 DR3 as a risk factor for HIV-related disease. Lancet 1988; 1:1185-8.
23. Kiepiela P, Leslie AJ, Honeyborne I, et al. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature 2004; 432:769-75.
24. Frahm N, Janes H, Friedrich DP, et al. Beneficial effects of protective HLA class I allele expression and breadth of epitope recognition after vaccination on HIV viral load post-infection. AIDS Vaccine 2010; P17.20. Atlanta, Georgia, USA.
25. Kaslow RA, Rivers C, Tang J, et al. Polymorphisms in HLA class I genes associated with both favorable prognosis of human immunodeficiency virus (HIV) type 1 infection and positive cytotoxic T-lymphocyte responses to ALVAC-HIV recombinant canarypox vaccines. J Virol 2001; 75:8681-9. (Pubitemid 32768972)
26. Riviere Y, McChesney MB, Porrot F, et al. Gag-specific cytotoxic responses to HIV type 1 are associated with a decreased risk of progression to AIDS-related complex or AIDS. AIDS Res Hum Retroviruses 1995; 11:903-7.
27. Kiepiela P, Ngumbela K, Thobakgale C, et al. CD81 T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 2007; 13:46-53. (Pubitemid 46067385)